we re noted. Ten months after the surgery , the patient was sy mptom -free.
• Figure A 36 -year-old man with a history of ehronie sinus itis complained of persistent left frontal headaches and left orbital pa in. T he patient de nied dip lopia, and physieal examination revealed full and symmetrie extraoe ular moveme nts. The patient' s visua l aeuity was intae t, and he did not have exophtha lmos.
Preoperative eorona l computed tomography dem onstrated opae ifiea tion of the left anterior et hmoi d air ee lls and a soft tissu e mass med ial to the left orbit (fig ure, A) . The medial wa ll of the left orbit was displ aeed laterally.
T he pa tie nt u nd erwent im ageguided funetiona l en doseopie sinus surge ry. A teleseopi e view revealed thiek greenis h see retions ex trudi ng fro m a mueoeele at the anterio r ethmoi d region adjaeent to the left lam ina papyraeea (fig ure, B) . W ith the ass istanee of co mputer image guidanee, a mierodebri der was used to earefully open the mueoeele and sue tion its eo ntents (fig ure, C) .
A thin left lamina papyraeea was visib le in the exenterated eav ity of the mu eoeele (figure, D). Ba llo ttement of the left globe , with the lids elosed, demonstrated within the eavi ty of the mueoeele a eorrespo ndi ng moveme nt at the thin lamina papyraeea. Th e bon e of the lamin a pap yraeea, however , was intaet, and no or bital eo ntents 
PATIENT-DAYS OF THERAPY*
Salagen Tahlet provide patients with effective, wcll-tolerated therapy Th mo t common ide elfeet i weaung, peciall at high r doscs. alagen Tablcts do not \ ork for e e one, and are contraindicated h Il lill' rurolled asthma i present and h Il miosi is und irable, Inaddilion, thefollowingadverseevents (~3% incidenee) were reporled at dosages of 15-30 mglday in the controlled e1inleal trials: Headaehe (11%).dyspepsia (7%), laerimation (6%), edema(5%), abdominal pain (4%). amblyopia (4%), vom iti ng(4%). pharyngitis (3%). hyperlensi on (3%).
The foll owingevents were reporledwith treated head andneek eaneer patients at incidenees of 1% 10 2% al dosages of 7.5 1030 mg/day: abnormal vision,eonjunetivitis, dysphagia, epistaxis, myalgias, pruritus, rash. sinusilis. taehyeardia. taste perversion,tremor, voice alleratian.
The lollowing events were reported rarely in freafed head and neek cancer patienfs (<1%): Causal relafion Is unknown.
Body odor, hypothermi a, mueous membrane abnormality, bradyeardia. ECG abnormality. palpi tations. syncape, anorexia, inereased appetile, esophagitis, gastroi ntesli nal disorder, tongue disorder , leukopenia. Iymphadenopalhy. anxiety, eonfusion, depressian, abnormai dreams. hyperkinesia,hypoesthesia. nervousness, paresthesias,speeeh disorder. twitehi ng. increased sputum, stridor. yawning, seborrhea, deafness, eye pai n.glaueoma, dysuri a, met rorrhagia. urinary impairm enl.
Inlong-term treat ment weretwopatients with underlyingeardiovaseular disease of whom oneexperieneed a myoeardial infaret andanolher an episode of syncape. The association withdrugis uncerl ain.
Sjogren's SyndromePatients: Ineontrolled studies. 376palientsreeei ved pilocarpine, of whom 5% were men and 95% were women. Race disl ribulion was84% Caueasian, 9%Ori ental,3% Bl ack,and 4%ofother origin. Mean agewas55 years. The majority of patientswere between 40 and 69 years (70%). 16% were 70 years and ol der and 14%were younger than40years of age.Ofthese patients, 161/629(89/376 reeeiving piloearpine) were over the ageof 65 years. The adverse events reporled by those over65yearsandthose 65years andyou nger were comparable exeept for notabl etrendsforurinary frequency, diar rhea, and dizziness. The ineidenees of urinary frequencyanddiarrhea in theelder ly were about double those in the non-elderly. The incidenee of dizziness was about threetimes as high in Iheelderly as in the non-elderly.These adverse experienees were not considered to be serious. In Ihe 2 plaeebocontrolled studies. themost common adverseeventsrelated 10 druguse wereswealing,uri naryfrequency. ehills,andvasodilatation (flushing).The most com monly reporledreasanfor patienl diseontinualionof trealment wassweating. Expeeted pharmaeologieelfeels of piloearpine inelude the following adverse experienees associatedwith SALAGEN' Tablets:
Pregnancy: Teratogenic etteets. Pregnancy Galegary G: Piloearpinewasassociated witha reduetion in the mean felal body weight and an inerease in theincidenee of skeletal varialions when given to pregnanl rats at a dosage of 90 mglkgl day (approximately 26times the maximum reeommended dose for a 50 kg human when eompared on Ihe basis of body surlaee area ( mg / mẽ sli mates). Theseetteets may have been seeondaryto matemal toxieity. In anolher study, oral admi nistration of pii oearpine 10 female rats during gestation and laetatian at a dosage of 36 mglkglday(approximately 10 times the maxi mum reeommended dose for a 50 kg human when eomparedon thebasis of body surlaee area ( mg / m~estimates) resulted in an inereased incidenee of stillbirl hs: deereased neonatal survival and redueed mean body weight of pupswere observed al dosages of 18 mglkg/day (approxirnately5 times themaximumreeommended dose for a 50 kg human when compared on the basi s of body surlaee area ( mgl m~est imales) andabove.Therearenoadequate andwell-eontrolled studies in pregnanl women. SALAGEN' Tabl ets should be used during pregnancy onlyif the potential benefit justines the potential risk to the fetus.
Nursing Mothers: II is not known whether this drug is excreted in humanmilk. Beeausemanydrugs areexereled inhumanmi lk and beeause of the potenl ial for serious adverse reaetions in nursing infants from SALAGEN" Iablets, a decision should be made whet herto diseontinue nur sing orto diseonti nuethedruq,takingintoaccount theimportance of the drug to themother.
Pediatric Use: Safetyand elfeetiveness in pediatrie patient s have not been established.
Geriatric Use: Headand Neek Ganeer Patients: Intheplacebc-controlled elinieal trials (see Clinieal Studies seetion in full preseribinginformation) themean ageof patients wasapproximately58years (range 1910 80). Of these patients, 97/369 (61/217 receiving pilocarpine) were over theage of 65 years. ln theheal thy volunteer studies. 1511 50 subjeels were over theageof65years. In bothstudy populations. the adverse events reporled bythose over 65yearsandthose 65 years and younger were comparable. Ofthe 15 elderiy vol unteers (5 women, 10 men). the5 women had higher Cmax's and AUC's thanthemen.
Sjogren'sSyndromePatients: Intheplaeebo-eonlrolled elinieal trials, the meanageof patient s wasapproxi mately 55years (range21to 85). The adverseeventsreporled by thoseover 65yearsand those 65yea rs and younger wereeomparable except fornotabletrends for urinary frequency. dierrhea, and dizziness (see AOVERSE REACTIONS seetion).
ADVERSE REAGTIONS: Head & Neek Caneer Patients'
In eontrolled studies, 217 pati enl s reeeived piloearpine,of whom 68% were men and 32%were women. Race distribution was91%Caueasian,8%Bl ack. and 1%of other origin. Meanagewas approximately58years.The majori tyof palients were between50 and 64 yea rs (51%),33% were 65 years and older and 16%were younger than 50 yea rs of age.
Themostfrequentadverseexperienees ass ociatedwithSALAGEN' Tablets wereaeonsequenee oftheexpeetedpharmaeologieelfeets ofpiloearpine. Dral administration of piloearpi neto male and femaleratsat a dosage of 18 mg/kgl day (approxi malely5 timesthe maximumreeommendeddose for a 50 kg human wheneompared on the basis of body surlaee area ( m g / m~estimates) resu lted in impaired reproductive funet ion.ineluding redueedferlili ty. decreased sper m motility. andmorphologie evidenee of abnormai sperm. It is unelearwhether the reduetionin ferlil itywasdueto elfeets on mal e ani mals,female animals,or bothmal es and females. In dogs, exposur e to pi locarpine at a dosage of 3 mglkgl day (approximately 3 times the maximum reeommended dose for a 50 kg human when eompared on the basis of body surlaee area ( mg / m~est imates) for sixmonths result edin evidenee of impairedspermatogenesis. The data obtainedin these studiessuggest that pil oearpine may impai r the fertili ty of male and female humans.
SA LAGEN' Tablets should be administered to individual s who are atlempting to eoneeive a ehild only if Ihe polential benefit justifies pol enti al impai rmenlof ferlility.
RHINOSCOPI C CLlNIC
Th is case demonstrates the utility of perform ing sinonasal surgery with the assistance of computer image guidance (VTI). Full evac uation of the mucocele without knowing its location in relatio n to the orbit would have been difficult , especially in light of the monocular view inherent in endoscopic sinus surgery. Confirmin g proper orientation and positioning with computer image guidance throu ghout the dissection improv ed the safety and effectiveness of this procedure. The advantages and disadvantages of intraoperative guidance systems have been discussed by Roth et al and Casiano.v' No techni cal advancement is without its limit ations, of course, so it is important to realize that a computer-guided system is only a useful adjunct to, not a substitute for, a thorou gh knowledge of sinonasal anatomy. The intraoperative image-guided system is particularly useful for sinonasal revision procedure s and when operating in close proximity to such vital structures as the brain and orbit.
